Home » Stocks » Novocure

Novocure Limited (NVCR)

Stock Price: $75.79 USD -0.38 (-0.50%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
After-hours: $76.12 +0.33 (0.44%) Jul 31, 7:56 PM

Stock Price Chart

Key Info

Market Cap 7.66B
Revenue (ttm) 409.05M
Net Income (ttm) 11.80M
Shares Out 100.44M
EPS (ttm) 0.11
PE Ratio 689.00
Forward PE 123.46
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $75.79
Previous Close $76.17
Change ($) -0.38
Change (%) -0.50%
Day's Open 76.97
Day's Range 74.08 - 77.26
Day's Volume 2,231,974
52-Week Range 53.40 - 98.84

More Stats

Market Cap 7.66B
Enterprise Value 7.48B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 100.44M
Float 83.39M
EPS (basic) 0.13
EPS (diluted) 0.11
FCF / Share 0.24
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.15%
FCF Yield 0.32%
Payout Ratio n/a
Shares Short 3.38M
Short Ratio 2.42
Short % of Float 3.62%
Beta 1.53
PE Ratio 689.00
Forward PE 123.46
P/FCF Ratio 314.30
PS Ratio 18.73
PB Ratio 31.62
Revenue 409.05M
Operating Income 7.30M
Net Income 11.80M
Free Cash Flow 24.38M
Net Cash 184.34M
Net Cash / Share 1.82
Gross Margin 64.31%
Operating Margin 1.78%
Profit Margin 2.90%
FCF Margin 5.96%
ROA 1.02%
ROE 5.53%
ROIC 1.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 4
Overweight 0
Hold 3
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$82.43*
(8.76% upside)
Low
73.0
Current: $75.79
High
93.0
Target: 82.43
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue35124817782.8933.0915.4910.36
Revenue Growth41.62%40.13%113.57%150.52%113.6%49.53%-
Gross Profit26316812136.6112.485.453.35
Operating Income-0.91-33.67-39.33-115-104-80.16-64.46
Net Income-7.23-63.56-61.66-132-112-80.68-77.37
Shares Outstanding97.2491.8388.5585.5630.4012.4911.50
Earnings Per Share-0.07-0.69-0.70-1.54-3.67-6.46-6.73
Operating Cash Flow26.62-1.87-33.13-108-99.88-74.24-52.72
Capital Expenditures-10.49-6.71-7.37-17.66-10.27-2.32-3.63
Free Cash Flow16.14-8.58-40.50-125-110-76.56-56.34
Cash & Equivalents328248185220270103177
Total Debt16414997.3496.2323.10--
Net Cash / Debt16598.7488.10124246103177
Assets479340265282307118189
Liabilities26222815214056.5220.0017.13
Book Value21811211414225197.88172
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Novocure Limited
Country United Kingdom
Employees 782
CEO Asaf Danziger

Stock Information

Ticker Symbol NVCR
Stock Exchange NASDAQ
Unique Identifier NASDAQ: NVCR
IPO Date October 2, 2015

Description

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) for the treatment of solid tumors. The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, Germany, Switzerland, Japan, and other countries. NovoCure Limited was founded in 2000 and is based in Saint Helier, the Channel Islands.